Testing a mechanism by blocking it
Researchers gave a GHRH-receptor antagonist or vehicle to six healthy young men and sampled blood repeatedly overnight. Blocking the receptor reduced pulsatile GH secretion and pulse amplitude without changing pulse frequency. The experiment provided direct evidence that endogenous GHRH contributes to spontaneous GH pulses. [1]
An antagonist blocks a signal; this was not a trial of using sermorelin to improve health. Keeping that distinction explicit prevents a mechanistic experiment from being mistaken for treatment evidence simply because the same pathway appears in both discussions.
Pulse size and pulse frequency are not interchangeable
The measured pulse features responded differently. [1] Our interpretation is that phrases such as “restores natural pulses” need to specify what they mean. Frequency, amplitude and total secretion are separate characteristics, and a change in one does not establish a change in all of them.
A useful analogy is a series of waves: waves can become taller without arriving more often. A summary that says only “more activity” loses information about the pattern. In research, preserving that information helps investigators distinguish hypotheses that would otherwise sound identical in ordinary language.
Mechanistic evidence has a proper role
The strength of this design lies in testing whether a signaling pathway participates in the observed physiology. Its conclusion should remain at that level. It does not establish improved sleep, stronger muscles, longer life or the safety of sustained treatment, because those were not the questions the experiment answered.
For a consumer, a mechanism can make a claim plausible enough to investigate. It should not make the claim certain enough to skip outcome evidence. Our evidence guide explains how to follow the chain from biological action to the particular benefit an advertisement implies.
Ask what “physiological” adds to the claim
If a treatment is described as physiological or natural, request a plain-language definition. Does the statement mean that it acts through a receptor, produces a particular hormone pattern or has demonstrated a patient benefit? Those are different assertions and require different kinds of support.
Do not let an appealing description settle a safety question. A medicine can act through an existing biological pathway and still need evidence about its risks, formulation and intended use. The consultation should connect the mechanism to a specific clinical objective, identify the limits of that connection and explain how both benefit and tolerability would be evaluated. This experiment supplies a piece of the biology, not an individualized prescription.
The nightly GHRH study examines a treatment context rather than receptor blockade. Reading the two separately helps preserve the difference between demonstrating a pathway and evaluating a particular exposure.